Is ageing a problematic hurdle to the efficacy of first-line atezolizumab plus bevacizumab in hepatocellular carcinoma?

Liver Int. 2022 Nov;42(11):2352-2353. doi: 10.1111/liv.15418.

Authors

Jihyun An¹, Ju H Shim^{2

3}

Affiliations

¹ Gastroenterology and Hepatology, Hanyang University College of Medicine, Guri, Gyeonggi, Republic of Korea.
² Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
³ Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

PMID: 36162086
DOI: 10.1111/liv.15418

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Aging
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bevacizumab / therapeutic use
Carcinoma, Hepatocellular* / drug therapy
Humans
Liver Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Bevacizumab
atezolizumab